nference and Rush University System for Health announce long-term partnership for Rush-hosted clinical analytics platform
On 2 September 2026, Rush University System for Health and nference announced a long-term partnership for a Rush-hosted analytics platform covering de-identified multimodal data on nearly 5 million patients. Rush is the first Illinois AMC to join nference's network alongside Mayo, Duke and Vanderbilt. No biopharma buyer or revenue terms are disclosed.
Where the rake sits
Rush keeps data custody, the hosting perimeter, and the researcher relationship; nference keeps the enrichment stack and the network effects across its AMC portfolio. The economic split with any downstream biopharma buyer is not disclosed in the release, so who actually captures the monetisable margin is not determinable from public facts.
What happened
- Announced 2 September 2026; long-term strategic collaboration between Rush University System for Health and nference (Cambridge, MA).
- Platform is Rush-hosted and covers de-identified longitudinal, multimodal data across nearly 5 million unique patients — clinical notes, radiology and pathology imaging, labs, medications, diagnostic reports, genomics, biospecimen-linked data, electrophysiology.
- nference contributes its federated software, data harmonisation and analytics infrastructure; Rush contributes the substrate and the hosting environment, and retains stewardship language in Matt Walsh's quote.
- Rush University Medical Center is the first Illinois-based academic medical center to partner with nference, joining Mayo Clinic, Duke Health, Vanderbilt, Emory, Banner, and Mercy Health in nference's AMC ecosystem.
- Announcement names Rush researchers and clinicians as the users; no external buyer, no biopharma engagement, no pricing or revenue-share terms are disclosed.
Who is involved
Cambridge, MA biomedical AI company; builds the nSights/nferX platform that structures unstructured EMR content (clinical notes, pathology images, ECG waveforms) inside partner hospitals under a federated architecture — it is the capability-stack partner, not the data owner.
~150 scientists/engineers/physicians as of 2020; raised $60M Series B in 2020 led by Mayo Clinic Ventures and NTT VC; 12-year strategic partnership with Mayo Clinic; ecosystem includes Duke Health and Emory Healthcare
Chicago academic health system (Rush University Medical Center plus Rush Oak Park and Rush Copley); the data owner in this deal, contributing de-identified longitudinal multimodal clinical data and hosting the platform on its own infrastructure. First Illinois-based AMC to partner with nference.
Rush University Medical Center FY2024 revenue $3.0B (Form 990); ~10,000 employees; 664 beds across the system
The reading
nference will architect the Rush-hosted platform using its federated software, data harmonization and analytics infrastructure to turn Rush's de-identified structured and unstructured clinical information into curated datasets for observational and prospective research; the enrichment layer is nference's, operating inside Rush's perimeter.
The stated payer-side decision is Rush's own researchers asking more ambitious questions and generating real-world evidence, with Matt Walsh describing the goal as giving Rush clinicians and scientists better tools to learn from patient-care data; no external pharma buyer or specific commercial decision (trial design, label expansion, target selection) is named in the Rush announcement, in contrast to nference's Mayo Clinic Platform arrangement which was explicitly aimed at biopharma drug discovery and development.
The press release is explicit that the platform is Rush-hosted and that Rush maintains stewardship of the data entrusted to it; the raw de-identified clinical data does not cross to nference, while nference's federated software and harmonization/analytics stack cross into Rush's environment.
Not determinable from public facts: with no disclosed external buyer or commercial terms, the deal reads at face value as Rush building internal research capability, and whether value is being left on the table depends on downstream pharma arrangements that have not been announced.
Why it matters
The interesting move is that Rush is buying the same shape of platform Mayo bought years earlier — one where the climb up the capability stack belongs to nference, not to the health system — and it is doing so before any external buyer has been named. If the platform stays inside Rush's research and care operations, this is a straightforward improve deal and the configuration question is academic; if it later opens onto biopharma the way Mayo's did (Anumana, Pramana), Rush will discover on the second deal that the architectural decisions that mattered were made on this one. Also, interesting to understand if and how training weights are regulated.
The argument this deal tests: The rake is decided before the negotiation begins
Related deals
- Tempus expands multi-year Merck collaboration giving Merck access to de-identified multimodal data and Lens platform2026-03-03
- Owkin licenses K Pro AI scientist and MOSAIC multimodal patient data to Servier for oncology research2026-09-11
- Flatiron Health renews NCCN real-world oncology data collaboration through 2028, deploys Flatiron Telescope2026-09-09
- Tempus AI expands multi-year collaboration giving Gilead enterprise-wide access to Lens platform and multimodal real-world oncology data2026-04-09
Sources
- prnewswire.com — primary
- intuitionlabs.ai — party background
- genomeweb.com — party background
- philanthropy.org — party background
- zoominfo.com — party background
Announced 2026-09-02 (date uncertain)